KLOW Peptide FAQ — 22 Questions on the Four-Peptide Research Blend
What is KLOW peptide?
KLOW peptide is a research co-formulation of four peptides — KPV, GHK-Cu, BPC-157 and TB-500 — in a single lyophilized (freeze-dried) vial, most commonly at 80 mg total (GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg). It is not a single molecule. Not FDA-approved. Supplied for laboratory research use only.
What is KLOW peptide used for?
In research contexts, the blend is associated with tissue repair, connective-tissue recovery and inflammatory modulation. Each component has its own published research basis: TB-500 / thymosin beta-4 for wound re-epithelialization [1], BPC-157 for tendon and ligament repair [2], KPV for NF-kappaB anti-inflammatory signaling [3], GHK-Cu for matrix synthesis and collagen induction [4]. The blend itself has no controlled trial.
What does the KLOW peptide do?
Each component acts on a distinct node: KPV suppresses NF-kappaB inflammatory transcription [3]; GHK-Cu drives collagen synthesis and broad matrix gene expression [4][5]; BPC-157 activates the VEGFR2 angiogenesis cascade [2]; TB-500 sequesters G-actin to facilitate cell migration and wound closure [1]. All four are single-component effects; no controlled study has tested whether the combination amplifies them.
What are the benefits of the KLOW peptide blend?
Component-attributed benefits from the individual literature: +42% wound re-epithelialization at four days and +61% at seven days (thymosin beta-4, rat model) [1]; improved tendon biomechanics and collagen organization after full transection (BPC-157, rat model) [2]; reduced NF-kappaB and cytokine output in inflamed epithelial cells (KPV, in vitro) [3]; increased collagen in 70% of treated women vs 50% for vitamin C (GHK-Cu topical) [4]. All extrapolated to the blend; not measured for the blend directly.
What are KLOW peptide benefits and side effects?
Benefits from the component literature are summarized on the effects page. Frequently reported community signals (anecdotal, not clinical evidence): tendon and joint recovery, reduced achiness, a broadly anti-inflammatory feeling. Adverse effects reported by the research-use community include injection-site redness and swelling, initial fatigue, mild headache and occasional nausea — all generally described as transient and minor. The WADA prohibition (via the TB-500 arm) and the pro-angiogenic caution in cancer contexts are the two most significant safety considerations from the component literature.
What are the side effects of the KLOW peptide?
Human safety data for the blend are absent — no clinical trial has been conducted. The BPC-157 arm's 2025 IV pilot in two adults documented no adverse events [6]. The thymosin beta-4 Phase 1 trial in 40 volunteers documented no dose-limiting toxicities up to 1260 mg IV [8]. Community reports (anecdotal, not clinical evidence) cite injection-site reactions as the most common adverse effect. TB-500 is prohibited by WADA [7]; three components are pro-angiogenic, which is a mechanistic caution in cancer contexts.
Is KLOW peptide safe?
The blend itself has never been tested for safety. The closest component-level human data: IV BPC-157 at 10-20 mg in two adults was well tolerated with no observed adverse events [6]; synthetic full-length thymosin beta-4 was tolerated to 1260 mg IV in 40 healthy volunteers [8]. KPV and GHK-Cu have no formal human safety trials. The 2026 Sports Medicine review notes that unapproved musculoskeletal peptides including TB-500 have scarce human safety data with potential for serious harm [7].
Does KLOW peptide work?
The component literature establishes that each peptide has measurable biological activity in its studied models: thymosin beta-4 accelerated wound healing in rats [1], BPC-157 improved tendon repair in rats [2], KPV reduced colitis severity in mice [3], GHK-Cu increased collagen in human skin cells [4]. Whether those effects occur with the four-peptide blend, or whether the combination produces anything beyond the single-component effects, has not been tested.
How long does it take for KLOW peptide to work?
In the foundational wound study, thymosin beta-4 showed a measurable re-epithelialization effect at four days (+42%) and a stronger one at seven days (+61%) [1]. BPC-157 tendon studies ran for multiple weeks. Community reports describe tendon and joint improvement over roughly three to four weeks. These are single-component timelines from animal models; the blend's timeline in humans has not been studied.
How long does it take to see results from KLOW peptide?
BPC-157 accelerated Achilles tendon healing across biomechanical and functional measures in rats over multi-week study periods [2]. Thymosin beta-4 wound data showed a 42% re-epithelialization increase at four days [1]. Community accounts describe three to four weeks for joint and tendon improvement. No human-controlled timeline data exist for the KLOW peptide blend.
How much KLOW peptide per day?
No validated human dose exists for the blend. Component research doses are described in the dosage section: thymosin beta-4 was tested in humans at 42-1260 mg IV [8]; BPC-157 was tested in two adults at 10-20 mg IV [6]; rodent doses for BPC-157 ran from 10 pg to 10 microg/rat/day [2]. These are research-context figures, not a dose recommendation.
How many mg of KLOW peptide per day?
The standard research vial is 80 mg total (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg). No human dose for the blend has been validated in any trial. Component-level doses from the rodent literature vary by compound and do not add directly to a reliable 'KLOW dose' given the pharmacokinetic mismatch between the four peptides.
What is the KLOW peptide dosage?
KPV is transported into intestinal epithelial cells via the di/tripeptide transporter PepT1, and nanomolar KPV inhibits NF-kappaB and MAP-kinase inflammatory signaling [3]. For dose-context research information for all four components, see the full KLOW peptide dosage page. No validated human dose exists for the blend.
What is the KLOW peptide dosage and frequency?
KLOW peptide dosage and frequency have not been validated for humans. Component literature references: thymosin beta-4 was dosed daily for 14 days in the Phase 1 human trial [8]; BPC-157 was dosed once daily IP in rat studies [2]; KPV was delivered orally in drinking water in mouse colitis models [3]; GHK-Cu topical data comes from six-month daily-application trials [11]. Frequency guidance for the blend does not exist.
How often should you take KLOW peptide?
KPV was studied with continuous oral delivery in rodent models [3]. Thymosin beta-4 was administered on a daily schedule in the human Phase 1 trial [8]. BPC-157 was given once daily IP in rat tendon studies [2]. There is no established frequency for the KLOW blend in any human trial. These component schedules are research context only.
Where do you inject KLOW peptide?
KPV, BPC-157 and TB-500 were studied via intraperitoneal (into the abdominal cavity) injection in animal models. Subcutaneous injection is the common research-handling route in the research-peptide community. GHK-Cu has been primarily studied topically. This site does not provide injection-site guidance; the blend is supplied for laboratory research use only.
How do you reconstitute KLOW peptide?
The research vial is supplied lyophilized (freeze-dried). Reconstitution for laboratory handling typically uses bacteriostatic water as the diluent. A theoretical consideration: GHK-Cu carries a chelated copper(II) ion, which can participate in oxidation reactions in solution; co-dissolving it with three other peptides in one vial raises an uncharacterized compatibility question [4][5]. This site provides research context, not reconstitution instructions.
What is in the 80mg KLOW peptide vial?
The canonical 80 mg KLOW research vial: GHK-Cu 50 mg (62.5% by mass, the mass-dominant copper tripeptide), BPC-157 10 mg (12.5%, the 15-amino-acid angiogenic peptide), TB-500 10 mg (12.5%, the seven-amino-acid actin-binding fragment), KPV 10 mg (12.5%, the tripeptide anti-inflammatory). Each component's identity and role is detailed on the blend components page.
Is a BPC-157 and TB-500 blend synergistic?
No controlled study has tested BPC-157 and TB-500 together, let alone the full four-peptide KLOW combination. The theoretical rationale is that BPC-157 drives angiogenesis (VEGFR2 pathway) [2] while thymosin beta-4 / TB-500 drives cell migration via G-actin sequestration [1] — complementary steps in the same repair cascade. Whether this translates to synergy in a real model has not been measured.
What is the difference between TB-500 and thymosin beta-4?
Thymosin beta-4 (Tbeta4) is a 43-amino-acid native protein. TB-500 is a synthetic N-acetylated seven-amino-acid fragment (Ac-LKKTET-Q) derived from Tbeta4's actin-binding region. TB-500 carries the G-actin sequestration motif. Full-length Tbeta4 additionally activates integrin-linked kinase and mobilizes epicardial progenitors. Most wound-healing efficacy data — including the +42% / +61% re-epithelialization findings [1] and the Phase 1 human trial [8] — are for the full-length native protein, not the fragment.
Why is KLOW peptide blue?
GHK-Cu (glycyl-histidyl-lysine copper complex) is a copper-chelated tripeptide. Copper(II) complexes are characteristically blue or blue-green in solution — a property of copper's d-orbital electron configuration. Since GHK-Cu is the mass-dominant component at 50 of 80 mg, the reconstituted KLOW vial takes on GHK-Cu's characteristic copper-blue color. The color reflects the copper chelation, not contamination or instability.
Does KLOW peptide help with weight loss?
No. None of the four KLOW components is a GLP-1 receptor agonist (the receptor class involved in appetite and metabolic regulation) or an established weight-loss agent. The blend's research context is tissue repair and inflammatory modulation, not weight management or metabolism. Any association of KLOW with weight loss is unsupported by the component literature.